2020
Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Dosoretz A, Shafman T, Gross C, Yu J, Meadows H, Decker R, Mak R, Kann B. Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e90. DOI: 10.1016/j.ijrobp.2020.07.1190.Peer-Reviewed Original Research
2019
An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Kann B, Dosoretz A, Shafman T, Gross C, Yu J, Decker R. An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s145-s146. DOI: 10.1016/j.ijrobp.2019.06.146.Peer-Reviewed Original Research
2016
A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original Research